“APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells”, Baghdad Sci.J, vol. 21, no. 8, p. 2551, Aug. 2024, doi: 10.21123/bsj.2024.10135.